At Biognosys, we believe that we can dramatically improve human health by deciphering the biological complexity of diseases. By providing access to the proteome on all levels, we enable life science researchers and drug hunters to unlock true discoveries.
We push the boundaries of what is possible with our proteomics solutions to help usher in a new age of bioengineering and precision medicine.
When we look at the proteome differently, we envision a better world!
To learn more about our vision, mission, and values, watch our new corporate video and visit: biognosys.com/our-story/
German life sciences magazine Transkript Laborwelt interviewed our Chief Business Officer Kristina Beeler, Ph.D., about the emerging wave of precision proteomics.
Read Full Magazine Issue (German language only)
The novel particle-based P2 Plasma Enrichment System achieves the highest reported proteome enrichment with greater reproducibility than any other protein corona-based workflow. The optimized single-well sample preparation, combined with optimized particle surface, stabilizes the labile protein corona and provides exceptional quantitative accuracy.
The brochure provides an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
Poster 3923/19 presented at AACR 2022
Presenter: Jakob Vowinckel
Session: PO.CH03.01 Proteomics, Signaling Networks, and Biomarker Discovery
Date: April 13
Preclinical drug development involves in-vivo discovery studies whereby essential model organisms, including mouse and rat help to understand human biology and disease. Despite genetic similarities, distinctions in gene expression between humans and relevant model organisms underscore the challenge of translatability.
Our latest white paper highlights our advanced plasma proteomics capabilities, driven by the P2 Enrichment System. The study demonstrates how TrueDiscovery® Plasma Biomarker Discovery services achieve an optimal balance between depth, throughput, and sensitivity, enabling their application in informed clinical decision-making.
This poster, shown at the American Society of Hematology 2023 Annual Meeting with Roche and the University of Basel, delves into the impact of rhPTX2 immunotherapy on mouse Myeloproliferative neoplasms. It leverages insights from plasma proteome profiling generated with our TrueDiscovery® platform.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
